These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 24935992)

  • 1. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain.
    Warnock GI; Aerts J; Bahri MA; Bretin F; Lemaire C; Giacomelli F; Mievis F; Mestdagh N; Buchanan T; Valade A; Mercier J; Wood M; Gillard M; Seret A; Luxen A; Salmon E; Plenevaux A
    J Nucl Med; 2014 Aug; 55(8):1336-41. PubMed ID: 24935992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the In Vivo Specificity of [
    Serrano ME; Becker G; Bahri MA; Seret A; Mestdagh N; Mercier J; Mievis F; Giacomelli F; Lemaire C; Salmon E; Luxen A; Plenevaux A
    Molecules; 2019 May; 24(9):. PubMed ID: 31052478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain.
    Nabulsi NB; Mercier J; Holden D; Carré S; Najafzadeh S; Vandergeten MC; Lin SF; Deo A; Price N; Wood M; Lara-Jaime T; Montel F; Laruelle M; Carson RE; Hannestad J; Huang Y
    J Nucl Med; 2016 May; 57(5):777-84. PubMed ID: 26848175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers.
    Constantinescu CC; Tresse C; Zheng M; Gouasmat A; Carroll VM; Mistico L; Alagille D; Sandiego CM; Papin C; Marek K; Seibyl JP; Tamagnan GD; Barret O
    Mol Imaging Biol; 2019 Jun; 21(3):509-518. PubMed ID: 30084043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution and Radiation Dosimetry for the Novel SV2A Radiotracer [(18)F]UCB-H: First-in-Human Study.
    Bretin F; Bahri MA; Bernard C; Warnock G; Aerts J; Mestdagh N; Buchanan T; Otoul C; Koestler F; Mievis F; Giacomelli F; Degueldre C; Hustinx R; Luxen A; Seret A; Plenevaux A; Salmon E
    Mol Imaging Biol; 2015 Aug; 17(4):557-64. PubMed ID: 25595813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [
    Zheng C; Holden D; Zheng MQ; Pracitto R; Wilcox KC; Lindemann M; Felchner Z; Zhang L; Tong J; Fowles K; Finnema SJ; Nabulsi N; Carson RE; Huang Y; Cai Z
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1482-1496. PubMed ID: 34761284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and in vivo evaluation of [
    Li S; Cai Z; Zhang W; Holden D; Lin SF; Finnema SJ; Shirali A; Ropchan J; Carre S; Mercier J; Carson RE; Nabulsi N; Huang Y
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1952-1965. PubMed ID: 31175396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of [
    Serrano ME; Bahri MA; Becker G; Seret A; Mievis F; Giacomelli F; Lemaire C; Salmon E; Luxen A; Plenevaux A
    Mol Imaging Biol; 2019 Oct; 21(5):888-897. PubMed ID: 30460626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [(11)C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A.
    Estrada S; Lubberink M; Thibblin A; Sprycha M; Buchanan T; Mestdagh N; Kenda B; Mercier J; Provins L; Gillard M; Tytgat D; Antoni G
    Nucl Med Biol; 2016 Jun; 43(6):325-32. PubMed ID: 27260773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic Characterization of [
    Becker G; Warnier C; Serrano ME; Bahri MA; Mercier J; Lemaire C; Salmon E; Luxen A; Plenevaux A
    Mol Pharm; 2017 Aug; 14(8):2719-2725. PubMed ID: 28651055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity.
    Patel S; Knight A; Krause S; Teceno T; Tresse C; Li S; Cai Z; Gouasmat A; Carroll VM; Barret O; Gottmukkala V; Zhang W; Xiang X; Morley T; Huang Y; Passchier J
    Mol Imaging Biol; 2020 Aug; 22(4):832-841. PubMed ID: 31728839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands.
    Mercier J; Archen L; Bollu V; Carré S; Evrard Y; Jnoff E; Kenda B; Lallemand B; Michel P; Montel F; Moureau F; Price N; Quesnel Y; Sauvage X; Valade A; Provins L
    ChemMedChem; 2014 Apr; 9(4):693-8. PubMed ID: 24446373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.
    Chen MK; Mecca AP; Naganawa M; Finnema SJ; Toyonaga T; Lin SF; Najafzadeh S; Ropchan J; Lu Y; McDonald JW; Michalak HR; Nabulsi NB; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    JAMA Neurol; 2018 Oct; 75(10):1215-1224. PubMed ID: 30014145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring with [
    Serrano ME; Bahri MA; Becker G; Seret A; Germonpré C; Lemaire C; Giacomelli F; Mievis F; Luxen A; Salmon E; Rogister B; Raedt R; Plenevaux A
    Mol Imaging Biol; 2020 Oct; 22(5):1197-1207. PubMed ID: 32206990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of [
    Puuvuori E; Rokka J; Carlsson PO; Li Z; Eriksson J; Eriksson O
    Sci Rep; 2021 Dec; 11(1):24466. PubMed ID: 34963683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET.
    Thomsen MB; Jacobsen J; Lillethorup TP; Schacht AC; Simonsen M; Romero-Ramos M; Brooks DJ; Landau AM
    J Cereb Blood Flow Metab; 2021 Apr; 41(4):819-830. PubMed ID: 32538280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic evaluation and test-retest reproducibility of [
    Finnema SJ; Nabulsi NB; Mercier J; Lin SF; Chen MK; Matuskey D; Gallezot JD; Henry S; Hannestad J; Huang Y; Carson RE
    J Cereb Blood Flow Metab; 2018 Nov; 38(11):2041-2052. PubMed ID: 28792356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of cerebral drug occupancy in humans using a single PET-scan: A [
    Marstrand-Joergensen MR; Laurell GL; Herrmann S; Nasser A; Johansen A; Lund A; Andersen TL; Knudsen GM; Pinborg LH
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3292-3304. PubMed ID: 38758370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates.
    Li S; Cai Z; Wu X; Holden D; Pracitto R; Kapinos M; Gao H; Labaree D; Nabulsi N; Carson RE; Huang Y
    ACS Chem Neurosci; 2019 Mar; 10(3):1544-1554. PubMed ID: 30396272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.